IRON — Disc Medicine, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1816736 ·
Last close
$76.57
Market Cap
$3.49B
52W High
$99.50
52W Low
$40.00
ADV30
1,354,627
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -64,161,000 | -59,535,000 | 699,488,000 | 89,983,000 | 95,238,000 |
| Jun 2026 | 0 | — | -65,075,000 | -59,532,000 | 735,071,000 | 98,676,000 | 90,907,000 |
| Mar 2026 | 0 | — | -69,524,000 | -63,504,000 | 750,213,000 | 88,913,000 | 61,784,000 |
| Dec 2025 | 0 | — | -66,970,000 | -60,531,000 | 806,879,000 | 91,145,000 | 67,053,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-197,536,000
Investing CF
$-93,419,000
Financing CF
$262,296,000
CapEx
$-933,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.54
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-633,222,000
Inventory
—
Receivables
—
ST Investments
$619,070,000
EBIT TTM
$-242,026,000
Pretax Income TTM
$-245,578,000
Interest Exp TTM
$3,552,000
Analysts
12
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -236,022,000 | -212,184,000 | 806,879,000 | 67,053,000 | 739,826,000 | -180,393,000 |
| Dec 2024 | 0 | -129,720,000 | -109,357,000 | 496,773,000 | 53,186,000 | 443,587,000 | -93,926,000 |
| Dec 2023 | 0 | -91,125,000 | -76,429,000 | 367,996,000 | 22,875,000 | 345,121,000 | -73,462,000 |
| Dec 2022 | 0 | -47,475,000 | -46,827,000 | 200,205,000 | 23,605,000 | 176,600,000 | -42,252,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-245,888,000
OpCashFlow TTM
—
Assets (Latest)
$735,071,000
Forward EPS
$-6.82
Max Pain — expiry 2026-12-18
max pain strike: $75.00 · spot: $77.98 · call oi: 2,917 · put oi: 1,688
Expected Move to 2026-12-18:
±$9.95
(12.76%) —
implied range
$68.03 –
$87.93
· ATM straddle on $80.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PBLS | Parabilis Medicines, Inc. | $3.49B | $28.25 | — |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.46B | $27.33 | — |
| ELVN | Enliven Therapeutics, Inc. | $3.45B | $46.85 | — |
| AMLX | Amylyx Pharmaceuticals, Inc. | $3.54B | $27.52 | — |
| VKTX | Viking Therapeutics, Inc. | $3.43B | $26.88 | — |
News headlines (Yahoo Finance, 1h cache)
Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-05 13:30 · Yahoo
Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual Meeting
2026-11-04 14:05 · Yahoo
Disc Medicine to Participate in Upcoming Investor Conferences
2026-11-02 13:30 · Yahoo
Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal Study
2026-10-22 03:30 · Yahoo
Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock
2026-10-21 00:52 · Yahoo
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday
2026-10-20 12:59 · Yahoo
Disc Medicine Stock Jumps After Phase 3 Trial Success And FDA Refiling Plan
2026-10-20 01:20 · Yahoo
Disc Medicine (IRON) APOLLO Win Puts Its Valuation Discount Back In Focus
2026-10-19 20:13 · Yahoo
Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants
2026-10-19 20:01 · Yahoo
What Could Disc Medicine (IRON) Reveal From Its Phase 3 APOLLO Trial?
2026-10-19 19:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.